Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CAMP - US13463J1016 - Common Stock

6.01 USD
+0.29 (+5.07%)
Last: 12/11/2025, 8:23:06 PM
5.89 USD
-0.12 (-2%)
After Hours: 12/11/2025, 8:23:06 PM
Fundamental Rating

2

Taking everything into account, CAMP scores 2 out of 10 in our fundamental rating. CAMP was compared to 531 industry peers in the Biotechnology industry. CAMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CAMP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CAMP has reported negative net income.
In the past year CAMP has reported a negative cash flow from operations.
CAMP had negative earnings in each of the past 5 years.
In multiple years CAMP reported negative operating cash flow during the last 5 years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With a Return On Assets value of -100.00%, CAMP is not doing good in the industry: 75.52% of the companies in the same industry are doing better.
CAMP has a worse Return On Equity (-127.50%) than 61.58% of its industry peers.
Industry RankSector Rank
ROA -100%
ROE -127.5%
ROIC N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CAMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K 30K

More info and screens

5

2. Health

2.1 Basic Checks

CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CAMP has about the same amount of shares outstanding.
Compared to 5 years ago, CAMP has more shares outstanding
The debt/assets ratio for CAMP has been reduced compared to a year ago.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 6.22 indicates that CAMP is not in any danger for bankruptcy at the moment.
CAMP's Altman-Z score of 6.22 is fine compared to the rest of the industry. CAMP outperforms 74.95% of its industry peers.
CAMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CAMP has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.22
ROIC/WACCN/A
WACC8.76%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CAMP has a Current Ratio of 5.59. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.59, CAMP is in line with its industry, outperforming 58.00% of the companies in the same industry.
A Quick Ratio of 5.59 indicates that CAMP has no problem at all paying its short term obligations.
The Quick ratio of CAMP (5.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.59
Quick Ratio 5.59
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.75% over the past year.
The Earnings Per Share has been growing slightly by 1.49% on average over the past years.
The Revenue for CAMP has decreased by -99.88% in the past year. This is quite bad
Measured over the past years, CAMP shows a very negative growth in Revenue. The Revenue has been decreasing by -75.10% on average per year.
EPS 1Y (TTM)79.75%
EPS 3Y42.01%
EPS 5Y1.49%
EPS Q2Q%97.73%
Revenue 1Y (TTM)-99.88%
Revenue growth 3Y-89.72%
Revenue growth 5Y-75.1%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CAMP will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.52% on average per year.
Based on estimates for the next years, CAMP will show a very negative growth in Revenue. The Revenue will decrease by -47.07% on average per year.
EPS Next Y-591.99%
EPS Next 2Y-86.95%
EPS Next 3Y-41.11%
EPS Next 5Y-21.52%
Revenue Next Year-99.95%
Revenue Next 2Y-89.28%
Revenue Next 3Y-87.21%
Revenue Next 5Y-47.07%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A cheap valuation may be justified as CAMP's earnings are expected to decrease with -41.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-86.95%
EPS Next 3Y-41.11%

More info and screens

0

5. Dividend

5.1 Amount

CAMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (12/11/2025, 8:23:06 PM)

After market: 5.89 -0.12 (-2%)

6.01

+0.29 (+5.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)05-11 2026-05-11
Inst Owners54.67%
Inst Owner Change100.38%
Ins Owners1.46%
Ins Owner Change0.83%
Market Cap281.75M
Revenue(TTM)350.00K
Net Income(TTM)-51.00M
Analysts85
Price Target8.67 (44.26%)
Short Float %1.15%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.36%
Min EPS beat(2)9.55%
Max EPS beat(2)13.17%
EPS beat(4)2
Avg EPS beat(4)-581.47%
Min EPS beat(4)-2111.25%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-296.37%
EPS beat(12)5
Avg EPS beat(12)-221.4%
EPS beat(16)9
Avg EPS beat(16)-140.29%
Revenue beat(2)2
Avg Revenue beat(2)1704.66%
Min Revenue beat(2)144.61%
Max Revenue beat(2)3264.71%
Revenue beat(4)3
Avg Revenue beat(4)912.54%
Min Revenue beat(4)-100%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)453.58%
Revenue beat(12)5
Avg Revenue beat(12)300.52%
Revenue beat(16)5
Avg Revenue beat(16)222.49%
PT rev (1m)0%
PT rev (3m)-40.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.45%
EPS NY rev (1m)-7.47%
EPS NY rev (3m)24.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-48%
Revenue NY rev (1m)15.53%
Revenue NY rev (3m)22.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 93.6
P/FCF N/A
P/OCF N/A
P/B 7.04
P/tB 7.04
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.06
BVpS0.85
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -100%
ROE -127.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.95%
Cap/Sales 17.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.59
Quick Ratio 5.59
Altman-Z 6.22
F-Score4
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)41.56%
Cap/Depr(5y)49.13%
Cap/Sales(3y)88.82%
Cap/Sales(5y)55.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.75%
EPS 3Y42.01%
EPS 5Y1.49%
EPS Q2Q%97.73%
EPS Next Y-591.99%
EPS Next 2Y-86.95%
EPS Next 3Y-41.11%
EPS Next 5Y-21.52%
Revenue 1Y (TTM)-99.88%
Revenue growth 3Y-89.72%
Revenue growth 5Y-75.1%
Sales Q2Q%N/A
Revenue Next Year-99.95%
Revenue Next 2Y-89.28%
Revenue Next 3Y-87.21%
Revenue Next 5Y-47.07%
EBIT growth 1Y-19.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.78%
EBIT Next 3Y-11.62%
EBIT Next 5YN/A
FCF growth 1Y10.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.02%
OCF growth 3YN/A
OCF growth 5YN/A

CAMP4 THERAPEUTICS CORP / CAMP FAQ

What is the fundamental rating for CAMP stock?

ChartMill assigns a fundamental rating of 2 / 10 to CAMP.


What is the valuation status for CAMP stock?

ChartMill assigns a valuation rating of 0 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.


Can you provide the profitability details for CAMP4 THERAPEUTICS CORP?

CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CAMP4 THERAPEUTICS CORP?

The Earnings per Share (EPS) of CAMP4 THERAPEUTICS CORP (CAMP) is expected to decline by -591.99% in the next year.